NeoImmuneTech, Inc. announced that the first patient has been dosed in a Phase 1b study of its lead drug candidate, NT-I7 (efineptakin alfa), a novel long-acting human interleukin-7 (IL-7), following CAR-T cell therapy tisagenlecleucel (Kymriah®) in patients with relapsed/refractory (r/r) Large B-Cell Lymphoma (LBCL). Diffuse Large B-Cell Lymphoma (DLBCL) is the most commonly occurring subtype of Non-Hodgkin Lymphoma (NHL), accounting for 25% to 30% of all NHL and >20,000 cases in the U.S. annually1. Despite improvement in therapeutic options, treatment is often not curative with as many as 50% of patients developing relapsed or refractory disease. This multicenter Phase 1b study will evaluate the safety, tolerability, and preliminary anti-tumor activity of NT-I7 administration following standard-of-care tisagenlecleucel CAR-T cell therapy, and determine the recommended Phase 2 dose of the combination for further future clinical development.